Brief: Kintor Pharma Completes First Patient Enrollment In Long-Term Safety Trial Of AGA Treatment KX-826
19/07/2023 14:25
July 19 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMA ANNOUNCES COMPLETION OF FIRST PATIENT
ENROLLMENT
IN LONG-TERM SAFETY PHASE III TRIAL OF KX-826 FOR TREATMENT OF
AGA
Source text for Eikon: ID:nPn8fvV9ba
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint